Clinical Trial Update: A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tolerability of multiple doses of BI 3006337 in adults with obesity and non-alcoholic fatty liver disease; the trial has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Obesity

Drugs mentioned

• BI 3006337

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-alcoholic Fatty Liver Disease, Obesity | Phase 1 | Status: COMPLETED | Results posted: 2025-12-05